Plasma Cell Leukemia: 2 Cases Reports and Review of Literature
Allali Asma, Mouamin Mouamin, Boufrioua Elghali, Oujidi Mohamed, Yahyaoui Hicham, Ait Ameur Mustapha, Chakour Mohamed
SAS J Med | 76-77
DOI : 10.21276/sasjm.2019.5.5.1
Plasma cell leukemia (PCL) is a rare disorder which develops spontaneously (primary PCL) or evolves in patients with
multiple myeloma (secondary PCL). It is defined by the presence of 2 × 109/L peripheral blood plasma cells or
plasmacytosis accounting for more than 20 % of the differential white cell count. PCL presents more often
extramedullary involvement, anemia, thrombocytopenia, hypercalcemia, as well as impaired renal function.
Cytogenetic abnormalities and mutations observed in PCL lead to escape from immune surveillance and independence
from the bone marrow microenvironment with changes in expression of adhesion molecules or chemokines receptors.
The outcome of PCL has improved with combination approaches with novel agents (including bortezomib and
immunomodulatory drugs, such as lenalidomide) and with autologous stem cell transplantation. Allogeneic
hematopoietic stem cell transplantation is currently available for young patients. This article is an overview of this rare
and severe disease and the different therapeutics options that are recommended through 2 observations.
Hereditary Hemochromatosis: About A Moroccan Family
Chabib FZ, Ben elbarhdadi I, Ajana FZ
SAS J Med | 78-80
DOI : 10.21276/sasjm.2019.5.5.2
Hereditary hemochromatosis is a genetic disease that causes iron overload and its precipitation in different organs. In
the African population, it is an extremely rare disease. To our knowledge, in the literature no case of North African
family has been reported, so we report our experience with a Moroccan family with hemochromatosis.